WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Lower risk of serious side-effects in trials of new targeted drugs

Details
Research
07 August 2012
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis. Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust analysed data from 36 Phase I trials run by the organisations' joint Drug Development Unit.
Read more ...

Rejected Alzheimer's drug shows new potential

Details
Research
01 August 2012
An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease.
Read more ...

Trial signals major milestone in hunt for new TB drugs

Details
Research
30 July 2012
A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published in the Lancet.
Read more ...

Bloodstream scavenger inhibits clotting without increased bleeding

Details
Research
23 July 2012
A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges - stopping the formation of blood clots without triggering equally threatening bleeding.
Read more ...

Physicians don't adequately monitor patients' medication adherence

Details
Research
16 July 2012
Patients' non-adherence to prescribed medication costs the U.S. health care system an estimated $290 billion annually and can lead to poor clinical outcomes, increased hospitalizations and higher mortality.
Read more ...

Drug fails to curb heart bypass complications, but surgery gets safer

Details
Research
10 July 2012
A drug designed to shield the heart from injury during bypass surgery failed to reduce deaths, strokes and other serious events among patients at high risk of complications, according to a large, prospective study lead by researchers at Duke University Medical Center.
Read more ...

Study finds drug warning labels need overhaul

Details
Research
05 July 2012
Many patients seem to ignore prescription drug warning labels with instructions that are critical for safe and effective use, according to a study by a Kansas State University researcher working with scientists at Michigan State University.
Read more ...

More Pharma News ...

  1. Patient-derived stem cells could improve drug research for Parkinson's
  2. A better way to test new treatments?
  3. Researchers block pathway to cancer cell replication
  4. Patients should be informed about effects of placebos
  5. New compound holds promise for treating Duchenne MD
  6. Metformin may lower cancer risk in people with Type 2 diabetes
  7. Common blood pressure drug linked to severe GI problems
  • Start
  • Prev
  • 257
  • 258
  • 259
  • 260
  • 261
  • 262
  • 263
  • 264
  • 265
  • 266
  • Next
  • End
Tahmeena

Business & Industry

  • AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
  • CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
  • Acquisition of Neogene Therapeutics completed

Research & Development

  • Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway
  • A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
  • 500,000 missed out on blood pressure lowering drugs during pandemic
  • Modified CRISPR-based enzymes improve the prospect of inserting entire genes into the genome to overcome diverse disease-causing mutations

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Research
  4. Commercial or communal: Why is outsourcing taboo for churches and pharmaceutical companies?

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.